Pasar al contenido principal

APLICACIONES TERAPEUTICAS DE NIS EN TRATAMIENTO DE CANCER

RTI2018-099343-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues

  • Riesco-Eizaguirre, Garcilaso
  • Santisteban, Pilar
  • Vieja, Antonio de la
The sodium/iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates active iodide transport into the thyroid gland and into several extrathyroidal tissues. NIS-mediated iodide uptake plays a pivotal role in the biosynthesis of thyroid hormones, of which iodide is an essential constituent. For 80 years, radioiodide has been used for the diagnosis and treatment of thyroid cancer, a successful theranostic agent that is extending its use to extrathyroidal malignancies. The purpose of this review is to focus on the most recent findings regarding the mechanisms that regulate NIS both in thyroid and extra-thyroidal tissues. Among other issues, we discuss the different transcriptional regulatory elements that govern NIS transcription in different tissues, the epigenetic modifications that regulate its expression, and the role that miRNAs play in fine-tuning NIS after being transcribed. A review on how hormones, cytokines, and iodide itself regulate NIS is provided. We also review the present stage of understanding NIS dysregulation in cancer, occupied mainly by convergent signaling pathways and by new insights in the route that NIS follows through different subcellular compartments to the plasma membrane. Furthermore, we cover NIS distribution and function in the increasing number of extrathyroidal tissues that express the symporter, as well as the role that NIS plays in tumor progression independently of its transport activity., The authors want to thank the support of the following Grants: PID2019-105303RB-I00/AEI/10.13039/501100011033 from MICIN and B2017/BMD3724 Tironet2 from Comunidad de Madrid (to P S); MICIU/FEDER RTI2018-099343-B-100 (to A D l V). The Asociación Española Contra el Cancer (AECC); GCB141423113) jointly awarded to P S and G R-E. PS, G R-E, and A D l V, belong to CIBERONC ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mesenchymal stem cells delivery in individuals with different pathologies: multimodal tracking, safety and future applications

  • Belmar-Lopez, Carolina
  • Vassaux, Georges
  • Medel-Martínez, Ana
  • Burnet, Jerome
  • Quintanilla, Miguel
  • Ramón y Cajal, Santiago
  • Hernández-Losa, Javier
  • Vieja, Antonio de la
  • Martín-Duque, Pilar
Due to their ease of isolation and their properties, mesenchymal stem cells (MSCs) have been widely investigated. MSCs have been proved capable of migration towards areas of inflammation, including tumors. Therefore, they have been suggested as vectors to carry therapies, specifically to neoplasias. As most of the individuals joining clinical trials that use MSCs for cancer and other pathologies are carefully recruited and do not suffer from other diseases, here we decided to study the safety and application of iv-injected MSCs in animals simultaneously induced with different inflammatory pathologies (diabetes, wound healing and tumors). We studied this by in vitro and in vivo approaches using different gene reporters (GFP, hNIS, and f-Luc) and non-invasive techniques (PET, BLI, or fluorescence). Our results found that MSCs reached different organs depending on the previously induced pathology. Moreover, we evaluated the property of MSCs to target tumors as vectors to deliver adenoviruses, including the interaction between tumor microenvironment and MSCs on their arrival. Mechanisms such as transdifferentiation, MSC fusion with cells, or paracrine processes after MSCs homing were studied, increasing the knowledge and safety of this new therapy for cancer., This research was supported by Instituto de Salud Carlos III (ISCIII) (PI19/01007 and DTS21/00130) and by Fondo Europeo de Desarrollo Regional (Feder) “Una manera de hacer Europa”. We also thank CIBER-BBN and CIBERONC an initiative funded by the VI National R&D&i Plan 2008–2011 financed by the Instituto de Salud Carlos III (ISCIII) with the assistance of the European Regional Development Fund. This study was also partially funded by the Aragon Government (Ph.D. Grant No.r B054/12) and cofounded by Aragon/FEDER 2014–2020 “Building Europe from Aragon”. This research was funded by Spanish Ministerio de Economía y Competitividad and European Regional Development Fund (FEDER) SAF2015-69964-R, RTI2018-099343-B-100 and from the CiberOnc by Instituto de Salud Carlos III (to ADlV).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Basolateral sorting of the sodium/Iodide symporter Is mediated by adaptor protein 1 clathrin adaptor complexes

  • Koumarianou, Petrina
  • Fernández-Méndez, Celia
  • Fajardo-Delgado, Dánae
  • Mielu, Lidia Mirella
  • Santisteban, Pilar
  • Vieja, Antonio de la
[Background]: The sodium/iodide symporter (NIS) is a transmembrane protein located on the basolateral membrane of thyrocytes. Despite its physiological and clinical relevance, little is known about the mechanisms that mediate NIS subcellular sorting. In the present study, we examined NIS basolateral trafficking in vitro using non-thyroid and thyroid epithelial cells. [Methods]: Immunofluorescence and Western blotting were performed to analyze NIS subcellular location and function in cells grown in monolayers under unpolarized and/or polarized conditions. Strategic NIS residues were mutated, and binding of NIS to clathrin adaptor complexes was determined by immunoprecipitation. [Results]: We show that NIS reaches the plasma membrane (PM) through a thyrotropin-dependent mechanism 24 hours after treatment with the hormone. We demonstrate that NIS basolateral trafficking is a clathrin-mediated mechanism, in which the clathrin adaptor complexes AP-1 (A and B) sort NIS from the trans-Golgi network (TGN) and recycling endosomes (REs). Specifically, we show that the AP-1B μ1 subunit controls NIS basolateral sorting through common REs. In its absence, NIS is apically missorted but remains functional. Additionally, direct NIS basolateral transport from the TGN to the basolateral membrane is mediated by AP-1A through clathrin-coated vesicles that also carry the transferrin receptor. Loss of the μ1 subunit of AP-1A is functionally compensated by AP-1B. Furthermore, loss of both subunits diminishes NIS trafficking to the PM. Finally, we demonstrate that AP-1A binds to the L121 and LL562/563 residues on NIS, whereas AP-1B binds to L583. [Conclusions]: Our findings highlight the novel involvement of the clathrin-coated machinery in basolateral NIS trafficking. Given that AP-1A expression is reduced in tumors, and its expression correlates with that of NIS, these findings will help uncover new targets in thyroid cancer treatment., This work was supported by grants PID2019-105303RBI00/AEI/10.13039/501100011033 from Ministerio de Ciencia e Innovacio´n (MICIN) and B2017/BMD-3724, Tironet2-CM from Comunidad de Madrid (Spain) to P.S.; and SAF2015-69964-R, RTI2018-099343-B-100 from the MICIN, Spain, and Fondo Europeo de Desarrollo Regional to A.D.l.V. P.S. and A.D.l.V. laboratories are supported jointly by CIBERONC CB16/12/00326 from the Instituto de Salud Carlos III (ISCIII). P.K., C.F.-M., and L.M.M. held predoctoral fellowship from Ministerio de Economia y Competitividad, Universidad Auto´noma de Madrid (Spain) and CIBERONC, respectively. D.F.-D. holds a contract associated with Grant SAF2015-69964-R.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vitamin D induces SIRT1 activation through K610 deacetylation in colon cancer

  • García-Martínez, José Manuel
  • Chocarro-Calvo, Ana
  • Martínez-Useros, Javier
  • Fernandez-Aceñero, M. Jesús
  • Fiuza, M. Carmen
  • Cáceres-Rentero, José
  • Vieja, Antonio de la
  • Barbáchano, Antonio
  • Muñoz Terol, Alberto
  • Larriba, María Jesús
  • García-Jiménez, Custodia
Posttranslational modifications of epigenetic modifiers provide a flexible and timely mechanism for rapid adaptations to the dynamic environment of cancer cells. SIRT1 is an NAD+ -dependent epigenetic modifier whose activity is classically associated with healthy aging and longevity, but its function in cancer is not well understood. Here, we reveal that 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3 , calcitriol), the active metabolite of vitamin D (VD), promotes SIRT1 activation through auto-deacetylation in human colon carcinoma cells, and identify lysine 610 as an essential driver of SIRT1 activity. Remarkably, our data show that the post-translational control of SIRT1 activity mediates the antiproliferative action of 1,25(OH)2D3 . This effect is reproduced by the SIRT1 activator SRT1720, suggesting that SIRT1 activators may offer new therapeutic possibilities for colon cancer patients who are VD deficient or unresponsive. Moreover, this might be extrapolated to inflammation and other VD deficiency-associated and highly prevalent diseases in which SIRT1 plays a prominent role., Funding for this work was provided by the Agencia Estatal de Investigación (PID2019- 104867RB-I00 / AEI/10.13039/501100011033, RTI2018-099343-B-100 and PID2021-127645OAI00); Instituto de Salud Carlos III (CIBERONC, CB16/12/00273 and CB16/12/00326); Comunidad de Madrid (Ayudas Atracción de Talento 2017-T1/BMD-5334 and 2021-5A/BMD-20951; A385- DROPLET Young Reserchers R&D Project 2019 CAM-URJC; PRECICOLON-CM, P2022/BMD7212); Universidad Rey Juan Carlos (ADIPOMELM, Proyecto Puente de Investigación 2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Isolation and characterization of milk exosomes for use in advanced therapies

  • Medel-Martínez, Ana
  • Redrado-Osta, Ana
  • Crespo-Barreda, Alejandra
  • Sancho‐Albero, María
  • Sánchez, Lourdes
  • Sebastián, Víctor
  • Pardo, María
  • Vieja, Antonio de la
  • Martín-Duque, Pilar
Exosomes are cell-derived extracellular vesicles (EVs) with diameters between 30 and 120 nm. In recent years, several studies have evaluated the therapeutic potential of exosomes derived from different fluids due to their low immunogenicity and high biocompatibility. However, producing exosomes on a large scale is still challenging. One of the fluids from which they could be isolated in large quantities is milk. Moreover, regeneration is a well-known property of milk. The present work seeks to optimize a method for isolating exosomes from bovine and human milk, comparing different storage conditions and different extraction protocols. We found differences in the yield extraction associated with pre-storage milk conditions and observed some differences according to the processing agent. When we removed milk fat globules and added rennet before freezing, we obtained a cleaner final fraction. In summary, we attempted to optimize a rennet-based new milk–exosome isolation method and concluded that pre-treatment, followed by freezing of samples, yielded the best exosome population., This research was supported by Instituto de Salud Carlos III (ISCIII) (PI19/01007 and DTS21/00130) and ASPANOA and AECC grants. It was also supported by Fondo Europeo de Desarrollo Regional (Feder) “Una manera de hacer Europa”. We also thank CIBER-BBN, an initiative funded by the VI National R&D&i Plan 2008–2011, financed by the Instituto de Salud Carlos III (ISCIII), with the assistance of the European Regional Development Fund. A.d.l.V.’s work was supported by grants from the Spanish Ministerio de Ciencia e Innovacion (MICIN) and Fondo Europeo de Desarrollo Regional (FEDER) RTI2018-099343-B-100 and PID2021-125948OB-I00/AEI/10.13039/501100011033, and V.S. acknowledges the funding from Fundación Ramón Areces (XX concurso nacional-ciencias de la vida y la materia). M.S.-A. thanks the AECC for postdoctoral research fellowship funding (POSTD234966SANC), “Ayuda a Talento AECC 2023”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeted radioiodine therapy of ovarian cancer via the sodium/iodide symporter (NIS)

  • Mirela Mielu, Lidia
  • Rodal-Bravo, Lucía
  • Diego-Hernández, Cristina
  • Varona, Sarai
  • Fajardo-Delgado, Dánae
  • Hortiguela, Rafael
  • Torres-Ruiz, Mónica
  • Cuesta, Isabel
  • Pallares, Pilar
  • Santisteban, Pilar
  • García-Jiménez, Custodia
  • Martín-Duque, Pilar
  • Vieja, Antonio de la
[Objective] Ovarian cancer is the most lethal gynecological malignancy, but current treatments have not improved overall survival and recurrence rates. New therapies are needed and, in this context, we propose the use of the sodium/iodide symporter (NIS) that enables effective targeted Radioiodide therapy (RAI), as NIS is overexpressed in ovarian cancer., [Methods] Using datasets and patient samples of human ovarian tumors, we determine the expression of NIS and canonical epithelial markers. We characterized NIS expression and function in human derived cell lines and tested the in vivo functional expression of NIS using Single Photon Emission Computed Tomography (SPECT). We also compared the efficacy of RAI versus chemotherapeutic treatments (cisplatin and paclitaxel) in mouse models., [Results] Human ovarian tumors expressed NIS, predominantly in a non-glycosylated form, with plasma membrane localization. Datasets and RNAseq confirmed NIS expression in ovarian epithelial tumors. Functional NIS expression was observed both in vitro and in vivo. In preclinical ovarian cancer mouse models, RAI therapy with 131I greatly reduced or eliminated tumors, was more effective, and had fewer secondary effects than classical treatments (cisplatin and paclitaxel), although both could be combined., [Conclusions] Our findings highlight that RAI through NIS could serve as a therapeutic agent in ovarian cancer. Additionally, it may enable non-invasive imaging and monitoring of disease progression., This work was supported by grants from the Spanish Ministerio de Ciencia e Innovacion (MICIN) and Fondo Europeo de Desarrollo Regional (FEDER) RTI2018–099343-B-100 and PID2023-151128OB-I00/AEI/10.13039/501100011033 to ADlV., PID2019–105303RBI00/AEI/10.13039/501100011033 to P.S., and PID2019–104867RB-I00/AEI/10.13039/501100011033 and PRECICOLON-CM P2022/BMD7212 to C.G-J., as well as CIBERONC CB16/12/00326 from Instituto de Salud Carlos III (ISCIII) to ADlV and P.S. Predoctoral fellowship from CIBERONC to L.M.M. Instituto de Salud Carlos III (ISCIII) (AESI 2024 PI24CIII/00046) and AECC grants Aragon/FEDER 2014–2020 “Building Europe from Aragon”, Spain to PM-D. This work was performed as partial fulfillment of the doctoral thesis of LMM at the Universidad Autonoma de Madrid (UAM) in Spain., Peer reviewed